Abstract: An oral once-per-day single dosage unit for treating the symptoms of rhinitis expertly formulated with a nasal decongestant and antihistamine. Preferably, the antihistamine is non-sedating.

Abstract: A pharmaceutical composition for use in the prevention of or in the treatment of infection by yeasts of the genus Malassezia comprises a chitin soluble extract (CSE), optionally together with a suitable pharmaceutical carrier. The composition is particularly useful for the treatment and prevention of Seborrheic dermatitis. Also described is a method for treating or preventing the Seborrheic dermatitis caused by yeasts of the genus Malassezia comprising the step of topically applying the pharmaceutical composition of the invention to the area infected by or susceptible to infection by the yeasts.

Abstract: The present invention relates to growing and testing microorganisms in which an anti-capsule compound is used in order to prevent false positive results. The present invention is suited for the characterization of commonly encountered microorganisms which commonly produce capsules (e.g., Kkebsiella, Enterobacter, Escherichia, Burkholderia, Pseudomonas, Sphingobacterium, Chryseobacterium, Bacillus, Micrococcus, Staphylococcus, Haemophilus, Neisseria, Gordona, Kytococcus, Jonesia, Rhodococcus, Corynebacterium, Streptococcus, Cellulomonas, Brevibacterium, Arcanobacterium, Tsukamurella, Acinetobacter, Cryptococcus, etc.), as well as organisms of medical, veterinary, commercial, and/or industrial importance from various and diverse environments.

Abstract: The invention concerns perfluoro-lower-alkyl derivatives of amino acids. A new synthetic route is provided for preparing .alpha.-aminotrifluoromethylketones, by converting .alpha.-amino acids to oxazolidin-5-ones which are then reacted with Ruppert's Reagent. Fluorinated derivatives of amino acids and peptides are shown to have a new property of inhibiting or inactivating metallo-.beta.-lactamase enzymes, and are thus valuable components of antibacterial formulations. Certain of the trifluoromethyl derivatives of amino acids are new compounds per se.

Abstract: Hexose derivatives are described which facilitate control over the stereochemistry of the glycosyl bond formed in the course of a solid phase glycosylation reaction. Methods for their use are also described.

Abstract: The invention provides a process for the preparation of long-chain alkyl glycosides, comprising reacting a glucose-containing reactant and a C.sub.8 -C.sub.18 fatty alcohol in the presence of a glucosidase and a reaction promoter effective to promote the formation of the alkyl glycoside when the promoter is present in an amount of less than about 50 wt % of the total reaction mixture.

Abstract: Microbe-inhibiting compositions including N-acetylglucosamine and methods of using them.

Abstract: Carbohydrate-containing polymers which can have an HLB* of from about 10 to about 20 are disclosed. The compounds comprise a hydrophilic polymer portion, a carbohydrate portion comprising from 1 to about 20 naturally occurring, identical or different, monosaccharide units, at least one bifunctional spacer coupling the carbohydrate portion to the hydrophilic polymer portion, and a potentiator moiety. The potentiator moiety can be is a crosslinking moiety located within the hydrophilic polymer or a hydrophobic, hydrophilic or ionic moiety. Processes for the preparation and use of such polymers are also disclosed.

Abstract: A water insoluble, biocompatible composition that includes the reaction product of a polyanionic polysaccharide and an activating agent.

Abstract: Hyaluronic acid, hyaluronate esters and salts thereof are sulfated such that the number of sulfate groups per disaccharide unit are in the range of from 0.5 to 3.5. The sulfated derivatives exhibit anticoagulant and cell adhesion reduction properties, and may be used to prepare biomaterials.

Abstract: This invention relates to a method of preparing a form of chitin that has consistent shape in the dry form, is treated chemically such that it will swell when exposed to water to form a gel. The gel can be dried to give the dry form. The gel formation upon absorption/swelling in the presence of water and drying to give the dried form is reversible. The extent of swelling can be varied by suitably varying the chemical treatment.

Abstract: Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: The present invention relates to a pharmaceutical composition (a marrow cell proliferation accelerator, a radioprotective agent, a therapeutic agent for thrombocytopenia) comprising a compound represented by the following formula (A), and to a therapeutic or prophylactic method (a method for accelerating marrow cell proliferation, a method for protecting human against radiation damage, a method for the treatment of thrombocytopenia) characterized in that an effective amount of a compound represented by the following formula (A) is administered to human: ##STR1## wherein R represents ##STR2## (wherein R.sub.2 represents H or OH, X is an integer of 0-26) or --(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1 is one of the substituents defined by the following (a) to (d):--CH.sub.2 (CH.sub.2).sub.Y CH.sub.3, (a)--CH(OH)(CH.sub.2).sub.Y CH.sub.3, (b)--CH(OH)(CH.sub.2).sub.Y CH(CH.sub.3).sub.2, (c)and--CH.dbd.CH(CH.sub.2).sub.Y CH.sub.3 (d)(wherein Y is an integer of 5-17).

Abstract: Hyaluronic acid or hyaluronic acid ester derivatives, wherein one or more hydroxy functions of its 1,4.beta.-D-glucuronic acid and 1,3-.beta.-N-acetyl-D-glucosamine alternating repeating units are esterified with a carboxyl group of succinic acid to form the succinic hemiester of hyaluronic acid or hyaluronic acid esters. These derivatives are used to prepare the corresponding heavy metal salts of succinic hemiesters of hyaluronic acid or with hyaluronic acid partial or total esters. These salts are used as active ingredients in the preparation of pharmaceutical compositions to be used as antibacterial and disinfectant agents for the treatment of wounds, burns and ophthalmia or as antiinflammatory agents in particular for the preparation of pharmaceutical compositions for the treatment of osteoarticular disorders.

Abstract: Novel polysaccharide compounds are disclosed for decorating biomolecular surfaces to increase isotropic size and mask antigenicity. The oligosaccharides may be synthesized as repeating disaccharide units, or may be derived by acid hydrolysis of naturally occurring polysaccharides. Such natural sources include chondroitins obtained from shark cartilage, or hyaluronic acid. The polyanionic sulfate groups contained in the sugar moieties impart negative charges which repel the molecules from the negatively charged wall of capillaries, to lengthen retention times of decorated drug molecules, such as crosslinked hemoglobin, in the peripheral circulation.

Abstract: A cytological fixative and dehydrating agent used for treating histological and cytological tissues for pathological diagnoses consists of a blend of from about 11 to 21% ethyl alcohol, from about 35 to 45% methyl alcohol and from about 40 to 50% by weight isopropyl alcohol. The treated tissue is subjected to further processing to render the cells in the tissue stable prior to placing the tissue upon a glass slide for pathological examination.

Abstract: The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoy l]-2-[(R)-3-octadecanoyloxytetradecanoylamino]-.beta.-D-glucopyranosyl]-2-[ (R)-3-hexadecanoyloxytetradecanoylamino]-D-glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.

Abstract: This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.

Abstract: The present invention discloses carbohydrates and carbohydrate analogs that bind to epidermal growth factor (EGF) receptors. Methods of using such carbohydrates or analogs for a variety of uses related to the EGF receptor are also provided. In preferred aspects of the present invention, methods for killing or inhibiting the growth of tumor cells with increased EGF receptor activity are disclosed.

Abstract: This invention provides a method of treating or preventing neoplastic diseases. The method comprises adminstering to a host in need of such treatment or prevention an effective amount of a Vitamin D.sub.3 analog of the Formula I wherein:X is H.sub.2 or CH.sub.2 ;Y is hydrogen, hydroxy or fluorine;Z is hydroxy;R.sub.1 and R.sub.2 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.1 and R.sub.2 together with C.sub.25 form a (C.sub.3 -C.sub.6) cycloalkyl or cyclofluoroalkyl;R.sub.3 and R.sub.4 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.3 and R.sub.4 together with C.sub.25' form a (C.sub.3 -C.sub.6)cycloalkyl or cyclofluoroalkyl;A is a single bond or a double bond;B.sub.1 is a single bond, an E-double bond, a Z-double bond or a triple bond; andB.sub.2 is a single bond, an E-double bond, a Z-double bond or a triple bond; or a prodrug thereof.